5:45 PM
 | 
Oct 16, 2012
 |  BC Extra  |  Company News

FDA panel votes in favor of Gattex for SBS

FDA's Gastrointestinal Drugs Advisory Committee voted 12-0 that Gattex teduglutide from NPS Pharmaceuticals Inc. (NASDAQ:NPSP) is effective and that the benefits outweigh its risks for treating adults with short bowel syndrome (SBS). The panel concluded that Gattex's reduction in the proportion of patients achieving...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >